Early Phase Clinical Trials: What the NC Cancer Hospital Has in Store

Clinical trials are extremely important to cancer patients who may have exhausted all other forms of treatment, yet still have active disease.  These patients can find hope in new treatments offered only through clinical trials and satisfaction in the fact that their participation may lead to safer, more effective treatments for future patients. 

Pictured left - Infusion Center under construction in the NC Cancer Hospital.

• Read about the new Early Phase Clinical Trial Unit that will be in the NC Cancer Hospital.

Focus on New Drugs - Phase I Trials

C14001 and C14003: Phase I first in human clinical trials of the oral aurora A kinase inhibitor MLN 8237 in patients with solid tumors or hematologic malignancies

Primary Investigators:

For solid tumors, Claire Dees, MD, 919-843-7714

For hematologic tumors, Thomas Shea, MD, 919-966-7746

Study Coordinators: Kim Keller, RN, 919-843-1969, or Jennifer Whitman, RN, 919-843-7146

 

CLCL161A2101: A Phase I, multi-center, open-label, dose-escalation study of oral LCL161 in adult patients with advanced solid tumors

Primary Investigator: Claire Dees, MD, 919-843-7714

Study Coordinator: Kim Keller, 919-843-1969

 

NO22068: IGF1R Antagonist R1507 + Multiple standard chemotherapies in patients with advanced malignancies

Primary Investigator: Claire Dees, MD, 919-843-7714

Study Coordinator: Kim Keller, 919-843-1969

 

20070411 (will open to accrual soon): A Phase I trial of an AMG 655 (monoclonal antibody to the death receptor DR5) + AMG 479 monoclonal antibody to IGF1R)

Primary Investigators: Richard Goldberg, MD, 919-843-7711, and Janine Davies, 919-843-6456

Study Coordinator: Kim Keller, 919-843-1969

 

LCCC 0621: Phase I trial of Everolimus plus FOLFOX and panitumumab

Primary Investigator: Bert O'Neil, MD, 919-966-4431

Study Coordinator: Kim Keller, 919-843-1969

 

Focus on Treatment of Central Nervous System Metastases

GLIA-001: A Phase 2, Multicenter, Exploratory Study, Evaluating the Treatment Effect of Surgery Plus GLIADEL® Wafer in Patients with Metastatic Brain Cancer

Primary Investigator: Matt Ewend, MD, 919-966-1374

Study Coordinator: Lucille Purser, 919-843-7112

 

Coming Soon: Phase II Study of novel agent for breast cancer brain metastases. Drs. Carey Anders, Charles Perou and William Zamboni are collaborating to test new drugs for brain metasases in animal models. A clinical trial for people with brain metastases is planned for the end of this year. Read more about pre-clinical studies.

 

View More Phase I Clinical Trials

Get to Know the CPO

Staff in UNC Lineberger's Clinical Protocol Office (CPO) support the design and conduct of oncology clinical trials.

The CPO is responsible for subject evaluation and registration, toxicity assessment and safety monitoring of novel therapeutics and patient education, among other tasks.

Read more about the CPO.